×

Global Lung Cancer Therapeutics Market 2015-2019: Key Vendors are AstraZeneca, Celgene, Eli Lilly, F. Hoffmann-La Roche and Pfizer

Dublin, Dec. 9, 2014 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/mplmp3/global_lung) has announced the addition of the "Global Lung Cancer Therapeutics Market 2015-2019" report to their offering.

The use of personalized medicine is a major trend in this market. It is based on the genetic structure of the patients, and has fewer adverse side effects compared to chemotherapy, which tends to destroy other healthy cells of the body while killing the malignant cancerous cells.

According to the report, the high unmet need for appropriate drugs is one of the major factors propelling the growth of the market. Current treatment options cannot cure the disease completely; hence, the mortality rate of lung cancer patients is high. Therefore, drugs that cause disease remission in patients are expected to significantly drive the growth of the market.

Further, the report states that the high cost of treatment is a major factor that restricts the growth of the market. The drugs that are used for the treatment of cancer are expensive and, hence, get poor response from patients. The patients also tend to withdraw themselves from expensive treatment regimens.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry.


Key Topics Covered:

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

04. Product Profiles

05. Market Research Methodology

06. Introduction

07. Disease Overview

08. Market Landscape

09. Market Segmentation by Disease Type

10. Market Segmentation by Molecule Type

11. Market Segmentation by Route of Administration

12. Geographical Segmentation

13. Buying Criteria

14. Market Growth Drivers

15. Drivers and their Impact

16. Market Challenges

17. Impact of Drivers and Challenges

18. Market Trends

19. Trends and their Impact

20. Vendor Landscape

21. Pipeline Portfolio

22. Key Vendor Analysis

23. Other Reports in this Series


Companies Mentioned:

  • Abbvie
  • Aetna
  • Agennix
  • Amgen
  • AstraZeneca
  • Boehringer Ingelheim
  • Celgene
  • Celldex
  • Eisai
  • Eli Lilly
  • F. Hoffmann-La Roche
  • GTx
  • GlaxoSmithKline
  • Helsinn
  • IMClone
  • Merck Serono
  • Novartis
  • OSI Pharmaceuticals
  • OncoGenex
  • Peregrine
  • Pfizer
  • Pierre Fabre
  • Qiagen
  • Sanofi
  • Synta
  • Telik
  • Teva Pharmaceutical


For more information visit http://www.researchandmarkets.com/research/mplmp3/global_lung

CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Sector: Lung Cancer

Source:Research and Markets